These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 136058)

  • 61. Circadian rhythms of fibrinogen and antithrombin III in liver cirrhosis.
    Pasqualetti P; Casale R
    Riv Eur Sci Med Farmacol; 1995; 17(4):125-9. PubMed ID: 8545565
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma.
    Mischke R; Wolling H
    Haemostasis; 2000; 30(3):123-30. PubMed ID: 11014962
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Disseminated intravascular coagulation: the application and utility of diagnostic tests.
    Ockelford PA; Carter CJ
    Semin Thromb Hemost; 1982 Jul; 8(3):198-216. PubMed ID: 6215711
    [No Abstract]   [Full Text] [Related]  

  • 64. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
    Bombeli T; Raddatz-Mueller P; Fehr J
    Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Minimal heparin cofactor activity in disseminated intravascular coagulation and cirrhosis.
    Braunstein KM; Eurenius K
    Am J Clin Pathol; 1976 Sep; 66(3):488-94. PubMed ID: 60879
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of heparin on chronically induced intravascular coagulation in dogs.
    Owen CA; Bowie EJ
    Am J Physiol; 1975 Aug; 229(2):449-54. PubMed ID: 1163671
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A personal perspective on hemostasis and thrombosis (1937-1981).
    Seegers WH
    Semin Thromb Hemost; 1981 Dec; 7(3-4):177-307. PubMed ID: 7034202
    [No Abstract]   [Full Text] [Related]  

  • 68. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
    Garcia-Avello A; Garcia-Frade LJ; Gandarias C; Ocaña J; Cancelas JA; Lasso M
    Thromb Res; 1994 Jan; 73(2):109-15. PubMed ID: 8171409
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Protease inhibitor and gastric cancer.
    Tsumoto S; Oyabu H; Kageyama T
    Bull Osaka Med Sch; 1983 Jul; 29(1):18-26. PubMed ID: 6204707
    [No Abstract]   [Full Text] [Related]  

  • 71. Identification and characterization of novel salivary thrombin inhibitors from the ixodidae tick, Haemaphysalis longicornis.
    Iwanaga S; Okada M; Isawa H; Morita A; Yuda M; Chinzei Y
    Eur J Biochem; 2003 May; 270(9):1926-34. PubMed ID: 12709051
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antithrombins: clinical aspects, chemical and biologic properties.
    Penner JA; Hunter MJ
    Prog Clin Biol Res; 1976; 5():277-300. PubMed ID: 61593
    [No Abstract]   [Full Text] [Related]  

  • 73. Mechanism of the anticoagulant, Cerastase F-4, isolated from Cerastes cerastes (Egyptian sand viper) venom.
    Daoud E; Tu AT; el-Asmar MF
    Thromb Res; 1986 Mar; 41(6):791-9. PubMed ID: 2939587
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
    Schwarz HP; Aiginger P; Kuzmits R
    Acta Med Austriaca; 1981; 8(1):22-5. PubMed ID: 6165218
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?
    Marongiu F; Conti M; Mameli G; Sorano GG; Cossu E; Cirillo R; Balestrieri A
    Thromb Res; 1990 Apr; 58(2):91-9. PubMed ID: 1693451
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Circadian rhythms of fibrinogen antithrombin III and plasminogen in chronic liver diseases of increasing severity.
    Pasqualetti P; Festuccia V; Acitelli P; Natali L; Collacciani A; Casale R
    Haemostasis; 1997; 27(3):140-8. PubMed ID: 9306131
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of fibrin(ogen) on thrombin generation and decay.
    Kremers RM; Wagenvoord RJ; Hemker HC
    Thromb Haemost; 2014 Sep; 112(3):486-94. PubMed ID: 24964786
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
    Lisman T; Leebeek FW; Mosnier LO; Bouma BN; Meijers JC; Janssen HL; Nieuwenhuis HK; De Groot PG
    Gastroenterology; 2001 Jul; 121(1):131-9. PubMed ID: 11438502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Actions and interactions of antithrombin and heparin.
    Rosenberg RD
    N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
    [No Abstract]   [Full Text] [Related]  

  • 80. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy.
    Bellart J; Gilabert R; Miralles RM; Monasterio J; Cabero L
    Gynecol Obstet Invest; 1998; 46(1):17-21. PubMed ID: 9692335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.